Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure

Andrea Giustina, Maurizio Volterrani, Filippo Manelli, Paolo Desenzani, Claudio Poiesi, Roberto Lorusso, Amerigo Giordano

Research output: Contribution to journalArticle

Abstract

Background: The aim of our study was to assess whether there could be any clinical and/or endocrine (spontaneous growth hormone [GH] secretion rate, baseline insulin-like growth factor-1 [IGF-1]) predictors and/or determinants of the acute effects of continuous intravenous infusion of recombinant human GH on hemodynamic parameters in 12 patients with dilated cardiomyopathy and congestive heart failure (CHF). Methods and Results: The study involved 12 male patients with chronic CHF (ischemic in 8 patients and idiopathic in 4). Ten patients were in New York Heart Association Functional class III or IV and 2 in class II. The first 24 hours were considered the control period; in fact, during the following 24 hours, all the patients underwent intravenous constant pump infusion of recombinant human GH. Blood samples for GH assay were taken every 20 minutes during the first night of the study (from 10 PM to 6 AM). Moreover, blood samples For GH assay were also taken during exogenous GH infusion. Blood samples For IGF-1 assays were taken at 8 AM of each of the 3 days of the study. Pulmonary artery pressure (PAP) and capillary wedge (PCWP) pressure, cardiac index, and arterial blood pressure were measured 30 minutes after right heart catheterization (baseline 1), at the end of the control period (baseline 2), and every 4 hours during GH infusion. A negative correlation has been found between mean nocturnal GH levels and baseline IGF-1 levels (r = -0.47, P = .124) and between mean nocturnal GH levels and both postinfusion absolute (r = -0.67, P <.05) and delta (postinfusion-preinfusion) (r = -0.58; P <005) IGF-1 levels. No significant correlations have been found between several parameters of liver function (albumin, bilirubin, and pseudocholinesterase) and mean nocturnal GH. However, baseline IGF-1 levels showed a negative significant correlation (r = -0.76, P <.01) with total bilirubin and a positive correlation (r = 0.72, P <.01) with pseudocholinesterase. Baseline IGF-1 levels showed a significant negative correlation with baseline mean PAP (r = -0.68, P <.05) and PCWP [r = -0.70, P <.05) and a positive correlation with baseline cardiac index [r = 0.71, P <.05). Baseline IGF-1 levels also showed a significant negative correlation with absolute mean PAP [r = -0.63, P <.05) and mean PCWP (r = -0.67, P <.05] after GH infusion. After GH infusion, IGF- 1 levels also negatively correlated with post-GH infusion mean PAP (r = - 0.50, P = .09) and mean PCWP (r = -0.66, P <.05). The positive correlation between either baseline or postinfusion IGF-1 and the postinfusion cardiac index (r = 0.40 and 0.43, respectively) did not reach statistical significance. Conclusions: GH has acute functional effects on the heart in patients with CHF, including both an increase in myocardial contractility and a decrease in vascular resistances, and among patients with CHF, those with low baseline IGF-1 are likely to have fewer beneficial effects from GH infusion.

Original languageEnglish
Pages (from-to)1035-1043
Number of pages9
JournalAmerican Heart Journal
Volume137
Issue number6
Publication statusPublished - 1999

Fingerprint

Growth Hormone
Heart Failure
Hemodynamics
Somatomedins
Pulmonary Artery
Pseudocholinesterase
Pressure
Human Growth Hormone
Bilirubin
Infusion Pumps
Pulmonary Wedge Pressure
Dilated Cardiomyopathy
Cardiac Catheterization
Insulin-Like Growth Factor I
Intravenous Infusions
Vascular Resistance
Albumins
Arterial Pressure

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Giustina, A., Volterrani, M., Manelli, F., Desenzani, P., Poiesi, C., Lorusso, R., & Giordano, A. (1999). Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. American Heart Journal, 137(6), 1035-1043.

Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. / Giustina, Andrea; Volterrani, Maurizio; Manelli, Filippo; Desenzani, Paolo; Poiesi, Claudio; Lorusso, Roberto; Giordano, Amerigo.

In: American Heart Journal, Vol. 137, No. 6, 1999, p. 1035-1043.

Research output: Contribution to journalArticle

Giustina, A, Volterrani, M, Manelli, F, Desenzani, P, Poiesi, C, Lorusso, R & Giordano, A 1999, 'Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure', American Heart Journal, vol. 137, no. 6, pp. 1035-1043.
Giustina A, Volterrani M, Manelli F, Desenzani P, Poiesi C, Lorusso R et al. Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. American Heart Journal. 1999;137(6):1035-1043.
Giustina, Andrea ; Volterrani, Maurizio ; Manelli, Filippo ; Desenzani, Paolo ; Poiesi, Claudio ; Lorusso, Roberto ; Giordano, Amerigo. / Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure. In: American Heart Journal. 1999 ; Vol. 137, No. 6. pp. 1035-1043.
@article{3bc12c337aac4fceac14063a3b8cc897,
title = "Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure",
abstract = "Background: The aim of our study was to assess whether there could be any clinical and/or endocrine (spontaneous growth hormone [GH] secretion rate, baseline insulin-like growth factor-1 [IGF-1]) predictors and/or determinants of the acute effects of continuous intravenous infusion of recombinant human GH on hemodynamic parameters in 12 patients with dilated cardiomyopathy and congestive heart failure (CHF). Methods and Results: The study involved 12 male patients with chronic CHF (ischemic in 8 patients and idiopathic in 4). Ten patients were in New York Heart Association Functional class III or IV and 2 in class II. The first 24 hours were considered the control period; in fact, during the following 24 hours, all the patients underwent intravenous constant pump infusion of recombinant human GH. Blood samples for GH assay were taken every 20 minutes during the first night of the study (from 10 PM to 6 AM). Moreover, blood samples For GH assay were also taken during exogenous GH infusion. Blood samples For IGF-1 assays were taken at 8 AM of each of the 3 days of the study. Pulmonary artery pressure (PAP) and capillary wedge (PCWP) pressure, cardiac index, and arterial blood pressure were measured 30 minutes after right heart catheterization (baseline 1), at the end of the control period (baseline 2), and every 4 hours during GH infusion. A negative correlation has been found between mean nocturnal GH levels and baseline IGF-1 levels (r = -0.47, P = .124) and between mean nocturnal GH levels and both postinfusion absolute (r = -0.67, P <.05) and delta (postinfusion-preinfusion) (r = -0.58; P <005) IGF-1 levels. No significant correlations have been found between several parameters of liver function (albumin, bilirubin, and pseudocholinesterase) and mean nocturnal GH. However, baseline IGF-1 levels showed a negative significant correlation (r = -0.76, P <.01) with total bilirubin and a positive correlation (r = 0.72, P <.01) with pseudocholinesterase. Baseline IGF-1 levels showed a significant negative correlation with baseline mean PAP (r = -0.68, P <.05) and PCWP [r = -0.70, P <.05) and a positive correlation with baseline cardiac index [r = 0.71, P <.05). Baseline IGF-1 levels also showed a significant negative correlation with absolute mean PAP [r = -0.63, P <.05) and mean PCWP (r = -0.67, P <.05] after GH infusion. After GH infusion, IGF- 1 levels also negatively correlated with post-GH infusion mean PAP (r = - 0.50, P = .09) and mean PCWP (r = -0.66, P <.05). The positive correlation between either baseline or postinfusion IGF-1 and the postinfusion cardiac index (r = 0.40 and 0.43, respectively) did not reach statistical significance. Conclusions: GH has acute functional effects on the heart in patients with CHF, including both an increase in myocardial contractility and a decrease in vascular resistances, and among patients with CHF, those with low baseline IGF-1 are likely to have fewer beneficial effects from GH infusion.",
author = "Andrea Giustina and Maurizio Volterrani and Filippo Manelli and Paolo Desenzani and Claudio Poiesi and Roberto Lorusso and Amerigo Giordano",
year = "1999",
language = "English",
volume = "137",
pages = "1035--1043",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure

AU - Giustina, Andrea

AU - Volterrani, Maurizio

AU - Manelli, Filippo

AU - Desenzani, Paolo

AU - Poiesi, Claudio

AU - Lorusso, Roberto

AU - Giordano, Amerigo

PY - 1999

Y1 - 1999

N2 - Background: The aim of our study was to assess whether there could be any clinical and/or endocrine (spontaneous growth hormone [GH] secretion rate, baseline insulin-like growth factor-1 [IGF-1]) predictors and/or determinants of the acute effects of continuous intravenous infusion of recombinant human GH on hemodynamic parameters in 12 patients with dilated cardiomyopathy and congestive heart failure (CHF). Methods and Results: The study involved 12 male patients with chronic CHF (ischemic in 8 patients and idiopathic in 4). Ten patients were in New York Heart Association Functional class III or IV and 2 in class II. The first 24 hours were considered the control period; in fact, during the following 24 hours, all the patients underwent intravenous constant pump infusion of recombinant human GH. Blood samples for GH assay were taken every 20 minutes during the first night of the study (from 10 PM to 6 AM). Moreover, blood samples For GH assay were also taken during exogenous GH infusion. Blood samples For IGF-1 assays were taken at 8 AM of each of the 3 days of the study. Pulmonary artery pressure (PAP) and capillary wedge (PCWP) pressure, cardiac index, and arterial blood pressure were measured 30 minutes after right heart catheterization (baseline 1), at the end of the control period (baseline 2), and every 4 hours during GH infusion. A negative correlation has been found between mean nocturnal GH levels and baseline IGF-1 levels (r = -0.47, P = .124) and between mean nocturnal GH levels and both postinfusion absolute (r = -0.67, P <.05) and delta (postinfusion-preinfusion) (r = -0.58; P <005) IGF-1 levels. No significant correlations have been found between several parameters of liver function (albumin, bilirubin, and pseudocholinesterase) and mean nocturnal GH. However, baseline IGF-1 levels showed a negative significant correlation (r = -0.76, P <.01) with total bilirubin and a positive correlation (r = 0.72, P <.01) with pseudocholinesterase. Baseline IGF-1 levels showed a significant negative correlation with baseline mean PAP (r = -0.68, P <.05) and PCWP [r = -0.70, P <.05) and a positive correlation with baseline cardiac index [r = 0.71, P <.05). Baseline IGF-1 levels also showed a significant negative correlation with absolute mean PAP [r = -0.63, P <.05) and mean PCWP (r = -0.67, P <.05] after GH infusion. After GH infusion, IGF- 1 levels also negatively correlated with post-GH infusion mean PAP (r = - 0.50, P = .09) and mean PCWP (r = -0.66, P <.05). The positive correlation between either baseline or postinfusion IGF-1 and the postinfusion cardiac index (r = 0.40 and 0.43, respectively) did not reach statistical significance. Conclusions: GH has acute functional effects on the heart in patients with CHF, including both an increase in myocardial contractility and a decrease in vascular resistances, and among patients with CHF, those with low baseline IGF-1 are likely to have fewer beneficial effects from GH infusion.

AB - Background: The aim of our study was to assess whether there could be any clinical and/or endocrine (spontaneous growth hormone [GH] secretion rate, baseline insulin-like growth factor-1 [IGF-1]) predictors and/or determinants of the acute effects of continuous intravenous infusion of recombinant human GH on hemodynamic parameters in 12 patients with dilated cardiomyopathy and congestive heart failure (CHF). Methods and Results: The study involved 12 male patients with chronic CHF (ischemic in 8 patients and idiopathic in 4). Ten patients were in New York Heart Association Functional class III or IV and 2 in class II. The first 24 hours were considered the control period; in fact, during the following 24 hours, all the patients underwent intravenous constant pump infusion of recombinant human GH. Blood samples for GH assay were taken every 20 minutes during the first night of the study (from 10 PM to 6 AM). Moreover, blood samples For GH assay were also taken during exogenous GH infusion. Blood samples For IGF-1 assays were taken at 8 AM of each of the 3 days of the study. Pulmonary artery pressure (PAP) and capillary wedge (PCWP) pressure, cardiac index, and arterial blood pressure were measured 30 minutes after right heart catheterization (baseline 1), at the end of the control period (baseline 2), and every 4 hours during GH infusion. A negative correlation has been found between mean nocturnal GH levels and baseline IGF-1 levels (r = -0.47, P = .124) and between mean nocturnal GH levels and both postinfusion absolute (r = -0.67, P <.05) and delta (postinfusion-preinfusion) (r = -0.58; P <005) IGF-1 levels. No significant correlations have been found between several parameters of liver function (albumin, bilirubin, and pseudocholinesterase) and mean nocturnal GH. However, baseline IGF-1 levels showed a negative significant correlation (r = -0.76, P <.01) with total bilirubin and a positive correlation (r = 0.72, P <.01) with pseudocholinesterase. Baseline IGF-1 levels showed a significant negative correlation with baseline mean PAP (r = -0.68, P <.05) and PCWP [r = -0.70, P <.05) and a positive correlation with baseline cardiac index [r = 0.71, P <.05). Baseline IGF-1 levels also showed a significant negative correlation with absolute mean PAP [r = -0.63, P <.05) and mean PCWP (r = -0.67, P <.05] after GH infusion. After GH infusion, IGF- 1 levels also negatively correlated with post-GH infusion mean PAP (r = - 0.50, P = .09) and mean PCWP (r = -0.66, P <.05). The positive correlation between either baseline or postinfusion IGF-1 and the postinfusion cardiac index (r = 0.40 and 0.43, respectively) did not reach statistical significance. Conclusions: GH has acute functional effects on the heart in patients with CHF, including both an increase in myocardial contractility and a decrease in vascular resistances, and among patients with CHF, those with low baseline IGF-1 are likely to have fewer beneficial effects from GH infusion.

UR - http://www.scopus.com/inward/record.url?scp=0033451246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033451246&partnerID=8YFLogxK

M3 - Article

C2 - 10347328

AN - SCOPUS:0033451246

VL - 137

SP - 1035

EP - 1043

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 6

ER -